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Simple Summary: Therapy resistance in head and neck squamous cell carcinoma (HNSCC) patients
is the main obstacle to achieve more effective treatments that improve survival and quality of life of
these patients. Therefore, it is of vital importance to unravel the molecular and cellular mechanisms by
which tumor cells acquire resistance to chemotherapy. We conducted a comparative proteomic study
involving cisplatin-resistant cells and cancer stem cells with the aim of identifying proteins potentially
implicated in the acquisition of cisplatin resistance. Through this study, we identified for the first
time tetraspanin-1 (TSPAN1) as an important protein involved in the development, progression and
chemoresistance of HNSCC tumors.
Abstract: Sensitization of resistant cells and cancer stem cells (CSCs) represents a major challenge
in cancer therapy. A proteomic study revealed tetraspanin-1 (TSPAN1) as a protein involved in
acquisition of cisplatin (CDDP) resistance (Data are available via ProteomeXchange with identifier
PXD020159). TSPAN1 was found to increase in CDDP-resistant cells, CSCs and biopsies from head and
neck squamous cell carcinoma (HNSCC) patients. TSPAN1 depletion in parental and CDDP-resistant
HNSCC cells reduced cell proliferation, induced apoptosis, decreased autophagy, sensitized to
chemotherapeutic agents and inhibited several signaling cascades, with phospho-SRC inhibition
being a major common target. Moreover, TSPAN1 depletion in vivo decreased the size and proliferation
of parental and CDDP-resistant tumors and reduced metastatic spreading. Notably, CDDP-resistant
tumors showed epithelial–mesenchymal transition (EMT) features that disappeared upon TSPAN1
inhibition, suggesting a link of TSPAN1 with EMT and metastasis. Immunohistochemical analysis
of HNSCC specimens further revealed that TSPAN1 expression was correlated with phospho-SRC
(pSRC), and inversely with E-cadherin, thus reinforcing TSPAN1 association with EMT. Overall,
TSPAN1 emerges as a novel oncogenic protein and a promising target for HNSCC therapy.
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1. Introduction
Head and neck squamous cell carcinoma (HNSCC) is a particularly aggressive cancer type since
approximately 60% of patients have locally advanced disease upon diagnosis and approximately
half of affected individuals do not survive more than five years after diagnosis [1]. Unfortunately,
chemotherapeutic choices for the treatment of primary HNSCC have not improved over the past
50 years. Current chemotherapeutic options for HNSCC patients comprise chemotherapy, based mainly
on cisplatin (CDDP) and also 5-fluorouracil, taxanes or cetuximab in certain metastatic tumors [2,3].
Recently, immunotherapeutic agents (nivolumab and pembrolizumab) have also been approved for
recurrent/metastasic HNSCC [4]. In general terms, the high aggressiveness of HNSCC has been closely
associated with the large genetic complexity and intratumor heterogeneity as well as the presence
of distinct cancer cell subpopulations within the tumors showing different cancer stem cell (CSC)
properties and resistance levels.
Resistance to stress, ultra-violet (UV) light, and chemotherapy or radiation treatment can be
intrinsic or acquired. There is a general belief that resistance appears through natural selection of
pre-existing mutant clones during stress. However, a novel type of resistance appears throughout
the administration of chemotherapeutic agents, which seems to be related to treatment failure in
cancer patients. Furthermore, the acquisition of resistance to one drug, usually favors the acquisition
of resistance to other unrelated compounds, suggesting that the mechanisms of therapy resistance
developed by cancer cells seem to follow a universal pattern against a wide variety of drugs [5,6].
CSCs are of particular relevance, emerging at the top level of the resistance scale since they are
refractory to most, if not all, conventional chemotherapeutic treatments and radiotherapy. Accumulating
studies show that various CSC markers and properties are crucial for tumor initiation, maintenance,
expansion, and invasion, as well as mediators of treatment resistance, thereby allowing CSCs to survive
in the most drastic conditions in vivo to further metastasize upon reaching an appropriate niche [7,8].
In particular, inhibition of key CSC markers such as Wnt, NANOG, CD44, CD133, CD55, ALDH1,
OCT3/4, SOX2, KLF4 or NOTCH1 sensitizes cancer stem cells to chemotherapy [9,10]. Consistently,
inhibition of CSC properties enhances the effects of chemotherapy [11].
Importantly, resistant phenotypes can be reverted to drug-sensitive phenotypes [12]. Consequently,
in terms of applicability and clinical efficacy, cancer treatments should be capable of effectively targeting
not only the bulk of cancer cells but also the subpopulations of drug-resistant cell clones, including CSCs.
In metabolomic and proteomic studies, our group has recently demonstrated common regulatory
pathways to distinguish resistant cancer cells (non-CSCs) and CSCs from parental cells using a breast
cancer model [13]. Hence, it is of major relevance to focus on those proteins present in resistant cancer
cells and CSCs in order to design more effective treatment strategies that might synergistically act
with standard chemotherapy [14]. With the idea of unraveling crucial proteins involved in HNSCC
chemoresistance, a proteomic study was performed using the following cell lines: CCL-138 (parental),
CCL-138-R (resistant to CDDP) and CSCs (derived from parental CCL-138 cells). Based on this
analysis, we identified tetraspanin-1 (TSPAN1) as one of the most significantly upregulated proteins
in CCL-138-R cells and CSCs compared to parental CCL-138 cells. Tetraspanins are a family of cell
surface receptors that comprise a total of 33 members involved in signal transduction [15]. The role of
tetraspanins in cancer has emerged in the last decade, being involved in proliferation, metastasis and
immune protection and, consequently, postulated as potential oncogenic proteins [16,17]. Recently,
some tetraspanin members have also been linked to chemoresistance. For example, TSPAN9 has been
found to suppress chemosensitivity to 5-fluorouracil [18]. Specifically, TSPAN1 has been proved to
be important for the development of prostate, colon and gastric cancer [17,19]. For the first time,
this study investigates the clinical and biological relevance of TSPAN1 in HNSCC, with a special
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focus on laryngeal and pharyngeal tumors. For this purpose, the impact of TSPAN1 inhibition was
functionally assessed both in vitro and in vivo using disease-relevant HNSCC models, and the clinical
role of TSPAN1 was also further explored in a large series of HNSCC patient samples.
2. Materials and Methods
2.1. Cell Lines and Culture Conditions
Fresh samples of normal and tumor tissue from patients surgically treated for squamous larynx
carcinoma were obtained from the Otorhinolaryngology department of Vall d´Hebron University
Hospital (HUVH) as described [20]. These patients had not previously undergone any radio- or
chemotherapeutic treatment before surgical intervention. All of them signed the informed consent for
the analysis and publication of the data derived from their samples. The present study was carried out
following the instructions and requirements of the declaration of Helsinki along with the approval of
the Ethical Committee of the HUVH (Ref: PR[AG]342/2016). Patient-derived cell lines were established
in culture.
The human pharyngeal cancer cell lines HTB-43 (FaDu) and CCL-138 (Detroit 562) were purchased
from the American Type Culture Collection (ATCC, Manassas, VA, USA), while the laryngeal cancer
cell line JHU029 Lucires-GFP (RRID: CVCL_5993) and the tongue cell line SSC-25 were kindly
provided by Dr. S. Aznar-Benitah (Institute for Research in Biomedicine Barcelona, Spain). All of
them were satisfactorily authenticated based on polymorphism of small repetitive tandem loci.
The above-mentioned HNSCC cell lines and their respective Cancer Stem Cells (CSCs) subpopulations
were cultured as previously described [20].
2.2. Drug Assay
To determine their respective IC50, JHU029, JHU029-R, HTB-43, HTB-43-R, CCL-138 and
CCL-138-R, cell lines were seeded at 15 × 103 cells per well into 96-well plates, and the primary
cell lines derived from patients at 10 × 103 cells per well. Twenty-four hours later, cells were exposed
in triplicate to CDDP (range 0–150 µM) or dasatinib (Sigma-Aldrich, Merck, Madrid, Spain) (0–3 µM)
for 48 h. Cellular viability was measured by MTS (AQueous MTS Reagent Powder, Promega Biotech
Iberica, Madrid, Spain) based on the rate of metabolic activity of the previously treated cells.
2.3. Proteomic Study
A comparative proteomic analysis of the following cell lines was performed: CCL-138, CCL-138-R
and CCL-138 CSCs by using three biological replicates for each of them. The proteomic study has been
carried out by the COS Centre (Centre for Omic Sciences, Tarragona, Spain).
2.4. Sample Preparation and LC-MS/MS Analyses
The proteomic study was carried out by the technological infrastructures of the Center for Omic
Sciences (COS, EURECAT, Tarragona, Spain). Cell lysis and protein solubilization was performed
with modified Pierce RIPA Buffer (Thermo Scientific, Waltham, MA, USA). Thus, 200 µL of lysis buffer
(25 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 1% SDS and protease and
phosphatases inhibitors) was added to cell pellets that were sonicated (Sonics & Materials, Vibra Cell,
Illkirch, France) for three cycles of 10 s repeated six times with 15-s pause intervals. Afterwards,
the suspension was centrifuged, the supernatants transferred to new tubes and protein concentration
was determined by the Lowry method. Then, 65 µg of protein from each sample was reduced with
4 mM DTT for 25 min at 56 ◦C and alkylated with 8 mM iodoacetamide for 30 min at 25 ◦C in the dark
and loaded in a polyacrylamide gel to remove detergents. Next, the gel slice containing unresolved
proteins was cut into small pieces and digested overnight at 37 ◦C with trypsin at an enzyme: protein
ratio of 1:100. After digestion, a small aliquot of 2 µg was purified using C18 zip-tip (Merck Life
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Science, Madrid, Spain) to check proper protein digestion by nanoLC-Orbitrap before following sample
preparation steps.
2.5. Peptide 10-Plex TMT Labeling
The remaining digested protein sample was desalted on C18 Sep-Pack column (Waters, Bedford,
MA, USA) using 80% acetonitrile, 20% water with 0.1% formic acid for elution. The eluted peptides
were dried in the Speed-Vac and labeled with TMT 10-plex labelling (Thermo Fisher Scientific, Waltham,
MA, USA) following manufacturer’s instructions.
To normalize all the samples, a pool was created by mixing an equally small aliquot of each
sample and then, 40 µg of this pool and 40 µg of each of the nine individual samples were labeled.
Next, a small aliquot of 5 µg from each labeled sample was mixed and purified using C18 zip-tip
(Millipore, Burlington, MA, USA) and analyzed by nanoLC-Orbitrap to check the labeling reaction.
2.6. Peptide Fractionation
The labeled peptides from each sample were mixed together and desalted on C18 Sep-Pack
column (Waters, Bedford, MA, USA) using 80% acetonitrile, 20% water with 0.1% formic acid for
elution. The TMT pooled sample was dried in the Speed-Vac and resuspended in rehydration buffer
(5% Glycerol and 1% v/v IPG strip Buffer 3-10NL), and subsequently fractionated by isoelectrofocusing
on an Off-Gel fractionator from Agilent Technologies through 12-well IPG strips (Nonlinear gradient
from pH 3 to 10) according to the supplier’s protocol. Initially, 13-cm-long IPG strips were hydrated
with 40 µL per well of the rehydration buffer. 200 µg of TMT pooled sample was loaded on the strip
(150 µL of sample in each well). The samples were focused at 50 µA, with voltages between 500 and
4500 V for a total of 20 kVh. After separation, each one of the 12 fractions obtained was desalted on
C18 Sep-Pack column (Waters, Bedford, MA, USA) using 80% acetonitrile, 20% water with 0.1% formic
acid for elution. Eluted fractions were resuspended in 50 µL of 0.1% formic acid.
2.7. NanoLC-(Orbitrap) MS Analysis
The 12 fractions obtained from Off-Gel fractionation method were separated on a trap nano-column
(100 µm I.D.; 2 cm length; 5 µm particle diameter, Thermo Fisher Scientific, San José, CA, USA),
and then separated onto a C-18 reversed phase (RP) nano-column (75 µm I.D.; 15 cm length; 3 µm
particle diameter, Nikkyo Technos Co. LTD, Tokyo, Japan). The chromatographic separation was
performed with a continuous acetonitrile gradient using Milli-Q water (0.1% FA) and ACN (0.1% FA)
as mobile phase. A flow rate of 300 nL/min was used to elute peptides for real time ionization and
peptide fragmentation on an LTQ-Orbitrap Velos Pro mass spectrometer (Thermo Fisher). An enhanced
FT-resolution spectrum (resolution = 30,000 FHMW) followed by two data dependent MS/MS scan
events was performed. One consists of an HCD fragmentation (40% NCE) and FT-MS/MS acquisition
(R = 15,000 FHMW) from most intense ten parent ions with a charge state rejection of 1 and dynamic
exclusion of 0.5 min, which is used for peptide quantification. The other event consists of a CID
fragmentation (35% NCE) and IT-MS/MS acquisition from the same most intense ten parent ions, which is
used for peptide identification. The 12 raw data files obtained were analyzed by Multidimensional
Protein Identification Technology (MudPIT) on Proteome Discoverer software v.1.4.0.288 (Thermo Fisher
Scientific). For protein identification, all MS and MS/MS spectra were analyzed using Mascot search
engine (version 2.5). Mascot was set up to search the SwissProt_2017_05.fasta database (554,515 entries),
restricting for human taxonomy (20,202 sequences) and assuming trypsin digestion. Two missed
cleavages were allowed and an error of 0.02 Da for FT-MS/MS fragment ion mass, 0.8 Da for IT-MS/MS
fragment ion mass and 10.0 ppm for a FT-MS parent ion mass were allowed. TMT-10plex on lysine
and N-termini were set as quantification modifications, oxidation of methionine and acetylation of
N-termini were set as dynamic modifications, whereas carbamidomethylation of cysteine was set
as static modifications. The false discovery rate (FDR) and protein probabilities were calculated by
Percolator software.
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The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium
via the PRIDE partner repository [21], dataset identifier PXD020159.
2.8. Protein Analysis
Total protein extracts used for Western blot analysis were obtained from subconfluent cells and
lysed with RIPA buffer (25 mM TrisCl, 150 mM NaCl, 1% Igepal, 1% sodium deoxycholate, 0.1%
SDS, pH 7.5, plus 2 mM full cocktail of protease and phosphatases inhibitors, Thermo Scientific).
The following primary antibodies were incubated overnight at 4 ◦C: TSPAN1 (ab96070), ATG5 (ab109490)
(Abcam, Cambridge, UK); LC3B (#3868), pScr (#6943), Src (#2109), pAKT (# 9271), AKT (#9272), PARP1
(#9542S), pERK1/2 (#9101L) (Cell Signaling Technology Europe Leiden, The Netherlands); SQSTM1
(p62) (SAB3500430), β-actin (A3854) (Sigma—Aldrich Química SL, Madrid, Spain); ERK1/2 (sc-514302),
Vinculin (sc-73614) (Santa Cruz Biotechnology, Heidelberg, Germany). The membranes were revealed
with Super Signal™West Pico PLUS Chemiluminescent Substrate (Thermo Scientific). Results were
confirmed in at least three independent experiments.
2.9. Transfections
Two hundred thousand HNSCC cells were transfected in reverse with 10 nM siRNA TSPAN1
(siTSPAN1) or 10 nM siRNA negative control (NC) (Integrated DNA Technologies) and 4 µL of
Lipofectamine RNAimax (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) per well for
6-well plates in OPTIMEM serum-free medium (Gibco, Thermo Fisher, Waltham, MA, USA). Extracts
were collected at 48–72 h after transfection. Furthermore, we used an additional siTSPAN1 (siTOOLs
Biotech, Planegg, Germany) to demonstrate independently the biological effect of TSPAN1 inhibition.
This siRNA complex pool (siPOOLs) consists of 30 optimally-designed siRNAs that has demonstrated
to efficiently remove off-target effects and improve reliability of the results [22]. For the construction
of the corresponding proliferation curves, six cell counts were performed every 1–3 days up to a
maximum of 12 days.
2.10. Colony Formation Assay
A total of 5 × 103 cells were seeded per well in triplicate in 6-well plates and the colony formation
was allowed to grow for 10–14 days. The quantification of the colonies was performed by fixation
with 4% paraformaldehyde, followed by staining with crystal violet (0.5% w/v in water) and quantified
colorimetrically (once treated with 15% acetic acid), at 595 nm in an Epoch spectrophotometer (Biotek,
Winooski, VT, USA). Results were confirmed in at least three independent experiments.
2.11. Quantitative Real-Time PCR (qRT-PCR)
Total RNA was extracted from transfected cells at 72 h post-transfection using MirVana kit
(Ambion, Austin, TX, USA). Subsequently, total RNA was treated with DNAse I using the DNA-free™
DNA Removal kit (Invitrogen, Thermo Fisher Scientific), according to the manufacturer’s instructions.
The cDNA was obtained from PCR amplification of 500 ng of total RNA (RIN ratio ≥ 8) using the
RevertAid H Minus First Strand cDNA Synthesis kit. The expression of TSPAN1 (Hs00371661_m1)
was analyzed by qRT-PCR using the expression of IPO8 (Hs00183533_m1) as an endogenous gene and
TaqMan™ Universal Master Mix II (Applied Biosystems, CA, USA; Thermo Fisher Scientific). Results
were confirmed in at least three independent experiments (each sample run in triplicate).
Apoptosis detection by flow cytometry and autophagy analysis by transmission electron
microscopy (TEM), were respectively described elsewhere [20,23].
2.12. Animal Models
Five-week-old female mice from NMRI-FOXn1 nu/nu strain (Janvier Labs, Saint Berthevin Cedex,
Le Genest-Saint-Isle, France) were used for in vivo studies. JHU029 and JHU029-R cell lines were
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both labeled with luciferase and GFP as previously described [24], and transfected with siTSPAN1 vs.
negative control (NC). Forty-eight hours post-transfection, 1 × 106 cells were injected in each flank of
each animal, at a final volume of 200 µL of PBS and Matrigel (1:1, v:v) (Life Sciences, Corning, NY, USA).
A total of 16 mice were included in the study, four mice for each of the following experimental groups:
JHU029 NC, JHU029 siTSPAN1, JHU029-R NC, JHU029-R siTSPAN1. Tumor volume was measured
every 2–4 days, for a total of 42 days, using an electronic calibrator. At the end point, the animals
were analyzed by IVIS Spectrum (Perkin Elmer, Waltham, MA, USA). Mice were sacrificed by cervical
dislocation. An autopsy was performed on all the animals to collect liver, spleen, kidneys, lungs, heart
and bones, which were analyzed by IVIS Spectrum for ex vivo detection of micrometastases.
2.13. Image Platform
Optical imaging studies were carried out by the Preclinical Imaging Platform technicians
(Lab Animal Service, Campus Vall d’Hebron, Barcelona, Spain). For bioluminescence studies, animals
were injected with an intraperitoneal injection of luciferin at a dose of 150 mg/kg body weight.
Then, the animals were anesthetized prior to the scans with an isoflurane mixture (5% during induction,
2% in maintenance). Air flow was 0.8 L/min. After the image acquisitions, the animals were returned to
their cages for recovery. All the procedures were performed following instructions from the institutional
ethic committee (Ref. CEEA 42/15). Images were analyzed by the Preclinical Imaging Platform staff with
Living Image® software, from Perkin Elmer. Study analysis consists in light radiance quantification.
Signals from the light sources were isolated and characterized. The kinetic curve of bioluminescence
chemical reaction was examined, searching for the highest signals in each light source. These signals
are theoretically proportional to the number of cells involved in the bioluminescence reaction. Analysis
units were photons (p)/second (s)/centimeter (cm2) /stereoradian (sr). These units are technically
corrected and allow comparisons between different studies.
2.14. Patients
Surgical tissue specimens, from 106 patients with laryngeal or pharyngeal squamous
cell carcinoma who underwent surgical treatment at the Hospital Universitario Central de
Asturias, were retrospectively collected in order to perform immunohistochemistry (IHC) studies.
All experimental procedures were conducted in accordance to the Declaration of Helsinki and
approved by the Institutional Ethics Committee of the Hospital Universitario Central de Asturias
(Ref. 141/19, project PI19/00560). Representative tissue sections were obtained from archival,
paraffin-embedded blocks, and the histological diagnosis was confirmed by an experienced pathologist.
Three morphologically representative areas were selected from each individual tumor block to construct
five tissue microarray (TMA) blocks. In addition, each TMA also contained three cores of normal
epithelium as an internal control. All patients had a single primary tumor, microscopically clear surgical
margins and received no treatment prior to surgery. All patients were habitual tobacco smokers,
65 moderate (1–50 pack/year) and 41 heavy (>50 pack/year); 98 were habitual alcohol drinkers and
57 out of 106 patients (54%) received postoperative radiotherapy. The clinicopathologic features of
HNSCC patients are summarized in Table S1. The stage of disease was determined after the surgical
resection of the tumor according to the TNM system of the International Union against Cancer
(7th Edition). The histological grade was determined according to the degree of differentiation of the
tumor (Broders’ classification).
2.15. IHC
The formalin-fixed, paraffin-embedded tissues were cut into 3-µm sections and dried on Flex
IHC microscope slides (Dako, Glostrup, Denmark). The sections were deparaffinized with standard
xylene and hydrated through graded alcohols into water. Antigen retrieval was performed using
Envision Flex Target Retrieval solution (Dako, Glostrup, Denmark), high pH. Staining was done at
room temperature on an automatic staining workstation (Dako Autostainer Plus), using the Dako
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EnVision Flex + Visualization System (Dako Autostainer, Denmark) with the following antibodies:
anti-TSPAN1 monoclonal antibody Clone HPA011909 (Sigma—Aldrich Química SL, Madrid, Spain)
at 1:50 dilution, anti-E-Cadherin (BD Biosciences #610181, San Jose, CA, USA) at 1:4000 dilution and
active SRC monoclonal antibody Clone 28 (Thermo Fisher Scientific #AHO0051) at 1:300 dilution.
The SRC antibody, which detects the active protein, has been previously described [25]. Counterstaining
with hematoxylin was the final step. Immunostaining was scored blinded to clinical data by two
independent observers. TSPAN1 and E-cadherin were scored as follows: quantity scores from 0 to 3
were respectively assigned if 0%, 1% to 10%, 11% to 50%, and 51% to 100% of the tumor cells showed
cytoplasmic staining, and the staining intensity was rated on a scale of 0 to 2 (0 = negative, 1 = weak,
2 = strong). The raw data were then converted to an Immunoreactive Score (IRS) by multiplying the
quantity and staining intensity scores. For E-cadherin, an IRS score equal to or above the median
(score 4) was considered high expression. TSPAN1 expression was dichotomized as negative (score 0)
vs positive (scores 1 to 6) expression. In addition, nuclear expression of TSPAN1 was recorded as
negative vs. positive. Active SRC staining showed a homogeneous distribution, and therefore a
semiquantitative scoring system based on staining intensity was applied: low (0, 1+), moderate (2+),
or high expression (3+).
2.16. Experimental Design and Statistical Rationale
In order to discover new proteins involved in HNSCC chemoresistance, a comparative proteomic
analysis was performed using CDDP-resistant cells (CCL-138-R) and CSCs in relation to control cells
(CCL-138). For protein quantification, the ratios between each TMT-label against 126-TMT label were
used. Protein quantification was normalized based on protein median and Log2 transformed for
statistical analysis. Statistical analysis was performed by using Mass Profiler Professional software
v. 14.5 from Agilent Technologies to find significant protein changes between the cell conditions
assayed. Two different statistical analyses were performed to cover the different experimental conditions
described. In first instance, One-way ANOVA and Post-Hoc analysis was applied to all cell groups.
Next, an unpaired T-test for CCL-138 CSCs vs CCL-138 and CCL-138-R vs CCL-138 was applied to
check differences between them. In both cases, a Benjamini-Hochberg p-value correction for multiple
comparisons was applied to reduce false-positive findings. Only those proteins that were quantified in
at least 2 out of 3 independent experiments were considered for statistical purposes.
To determine the relevance of TSPAN1 expression in both HNSCC cell lines and patients including
its possible relevance in the clinic, all the statistical analyses in patient samples and cell lines were
performed using the SPSS 15.0 software package (SPSS Inc., Chicago, IL, USA). The χ2 test and
Fisher’s exact test were used for comparison between categorical variables. For time-to-event analysis,
Kaplan–Meier curves were plotted. Differences between survival times were analyzed by the log-rank
method. Wilcoxon test was used as a non-parametric test for mean ranks comparisons. Unpaired
Student’s t-test was performed to compare means between two groups. All tests were two-tailed.
p values below 0.05 were considered statistically significant.
3. Results
3.1. TSPAN1 Protein Is Upregulated in CDDP-Resistant HNSCC Cells
In order to identify proteins that might potentially have a relevant role in cancer chemoresistance,
a proteomic analysis was performed to compare the proteins expressed in parental CCL-138 cells vs.
CSCs and CCL-138-R cells (CDDP-resistant cells). A total of 1535 proteins were identified in these
three cell groups (Table S2). One-way ANOVA showed that 476 proteins were differentially expressed
among at least two of these groups (Table S3). A Post-Hoc analysis revealed which of these proteins
were dysregulated in each group, by comparing CCL-138-R vs. CCL-138 (262 proteins), and CSC
vs. CCL-138 (363 proteins) (Tables S4 and S5). Finally, 36 proteins were commonly and differentially
expressed in CCL-138-R and CSCs compared to parental CCL-138 cells; 12 proteins were upregulated
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and 24 proteins downregulated (Figure 1A, Table S6). One of the most upregulated protein, a member
of the tetraspanin family, named TSPAN1, was primarily selected for its potential clinical interest
in various cancer models [26,27]. In order to explore the putative relevance of TSPAN1 in HNSCC,
TSPAN1 levels were compared in the following HNSCC cell lines: CCL-138, JHU029, HTB-43 and
SSC-25. The metastatic cell line CCL-138 derived from a pharyngeal cancer showed the highest TSPAN1
levels (Figure 1B, Figure S8). In order to verify the proteomic results, TSPAN1 expression was analyzed
by Western blot in the aforementioned HNSCC cell lines confirming that TSPAN1 was upregulated
in CCL-138-R, JHU029-R and HTB-43-R cells compared to their respective control cells (Figure 1C,
Figure S8). Moreover, TSPAN1 was upregulated in the second and third generation (G2 and G3) of
enriched CSCs in HTB-43 cells at protein level and also in G3 from HTB-43 and CCL-138 at mRNA
level, as compared to parental cells (Figure 1C,D). It should be noted that HTB-43 cell line has the
highest proliferative capacity in 3D conditions [28].
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Figure 1. TSPAN1 is revealed as a prot i i lved in head and neck squamous cell carcinoma
(HNSCC) chemoresistance and proliferation. (A) The proteomic study identified 36 proteins commonly
deregulated in CSCs and CDDP-resistant cells compared with parentals (P) cells, TSPAN1 was one of
the most highly upregulated protein. (B) Western blot analysis of TSPAN1 expresion in four different
HNSCC cells (CCL-138, JHU029, HTB-43 and SCC-25). (C) Western blot analysis confirmed proteomic
data verifying increased TSPAN1 expression in CDDP-resistant cells; and CSC G2 and G3 from the
HTB-43 cell line. (D) TSPAN1 mRNA levels in parental and CDDP-resistant HNSCC cells upon TSPAN1
depletion. Data were normalized to IPO8 (endogenous control), and relative to NC (negative control or
scramble) cells assigned the value of 1. TSPAN1 mRNA level for CSC from HTB-43 and CCL-138 cell
lines was also assessed. Unpaired two-tailed Student’s t-test, *** (p < 0.001). (E) Proliferation curves of
cells transduced with siTSPAN1 vs. non-targeted siRNA control (NC) are shown. (F) Colony number
quantification of HNSCC cell lines transduced with siTSPAN1 compared to the respective NC controls.
Unpaired two-tailed Student’s t-test, * (p < 0.05), ** (p < 0.01), *** (p < 0.001). OD: Optical Density
measured at 595 nm (Crystal violet).
The functional relevance of TSPAN1 was assessed by siRNA depletion in HNSCC cells. Transduced
parental JHU029, HTB-43 and CCL-138 cells and their respective CDDP-resistant variants with siTSPAN1
robustly decreased TSPAN1 mRNA levels by ~90% in all cell lines (Figure 1D). Cell proliferation
decreased in TSPAN1-depleted cells (Figure 1E), and the most potent reduction was observed in resistant
JHU029-R and HTB-43-R cells compared to parental cells (Figure 1E and Figure S1). Consistently,
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colony formation capacity was also significantly reduced upon TSPAN1 depletion in CDDP-resistant
and parental HNSCC cells (Figure 1F).
3.2. TSPAN1 Inhibition Induces Sensitivity of HNSCC Cells to Chemotherapeutic Agents
The effects of TSPAN1 depletion on drug response were analyzed in parental and resistant
JHU029, HTB-43 and CCL-138 cells. These cell lines showed levels of sensitization to CDDP that
vary between 14–43% IC50 reductions in relation to the control cells. Sensitization to CDDP was
observed by TSPAN1 depletion in all cell lines, with a higher effect in the respective resistant variants,
and HTB-43-R cells showing the highest sensitization (Figure 2A,B). In order to demonstrate that the
phenotypic effects observed by TSPAN1 inhibition using the previous siRNA was not due to off-target
effects, we tested an independent siRNA#2 against TSPAN1 (Integrated DNA Technologies, Coralville,
IA, USA). Moreover, a pool of 30 specific siRNAs against TSPAN1 (siPool) (siTOOLsBiotech, Planegg,
Germany) was also tested. TSPAN1 inhibition with these new siRNAs (siRNA#2 and siPool) decreased
cell proliferation and sensitized HNSCC cells to the effects of CDDP, corroborating our previous results
(Figure S2) [28]. The role of TSPAN1 on CDDP response was also explored in biopsy-derived cell
lines from laryngeal and pharyngeal cancer patients. We chose four biopsy-derived cell lines with
high levels of resistance to CDDP (IC50 values ranging 39–53 µM). According to our previous report,
IC50 values >15 µM were considered as highly resistant to CDDP [20]. All four biopsy-derived cell
lines showed CDDP sensitization upon TSPAN1 inhibition, with a range of 29–53% IC50 reductions in
comparison with control cells (Figure 2C,D). Therefore, TSPAN1 depletion sensitizes with a stronger
effect in biopsy-derived cell lines than in established CDDP-resistant HNSCC cell lines.
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Figure 2. TSPAN1 sensitizes S cells to P. ( ) TSP 1 depletion sensitizes parental and
resistant cells CCL-138, JHU029 and TB-43 to C P. representative experiment is shown from at
least three independent experiments. (B) Table summarizes the IC50 values (µM) from the plots shown
in panel A, the IC50 values are represented graphically as the percentage of sensitization relative to
control cells (assigned a value of 100%). (C) Sensitization of biopsy-derived HNSCC cell lines from
four CDDP-resistant cancer patients: P33, P13 and P74 (laryngeal biopsies) and P23 (pharyngeal
biopsy). A representative experiment is shown from at least three independent experiments. (D) Table
summarizes the IC50 values (µM) from the plots shown in panel C, the IC50 values are represented
graphically as the percentage of sensitization relative to control cells (assigned a value of 100%).
Cancers 2020, 12, 3269 10 of 20
Next, we investigated if the sensitizing action of TSPAN1 depletion could be extended to other
therapeutic drugs, such as dasatinib, a dual SRC/ABL kinase inhibitor actively tested in various clinical
trials, including HNSCC [29,30] (www.clinicaltrials.gov). TSPAN1 inhibition sensitized HNSCC cells
to dasatinib (Figure S3). Hence, the effect of TSPAN1 inhibition on drug sensitization is not restricted
to CDDP and, beyond dasatinib, it could also extend to other chemotherapeutic drugs.
3.3. TSPAN1 Depletion Induces Apoptosis in HNSCC Cells
TSPAN1 protein levels were effectively reduced by siTSPAN1 (Figure 3A, Figure 4A and Figure S8).
Evidence of apoptosis induction upon TSPAN1 inhibition emerged from PARP cleavage analysis
by Western blot (Figure 3A and Figure S8). The active form of PARP, cleaved PARP1 -indicative of
apoptosis activation-, was found to increase in all TSPAN1-depleted cell lines. To corroborate these
results, apoptosis was further evaluated by Annexin V through flow cytometry (FACS). Upon TSPAN1
inhibition, apoptosis increased in all cell lines except HTB-43-R, which was only observed in early
apoptosis, (Figure 3B). In CCL-138 cells, the early and late apoptosis represent 1.4% and 4.4%,
respectively (5.8% total), whereas these percentages slightly increased to 1.9% and 5.2% (7.1% total) in
the corresponding TSPAN1-depleted cells. For CCL-138-R cells, early and late apoptosis represent
1.5% and 2.1%, respectively (3.6% total), while apoptosis further increased in TSPAN1-depleted cells to
reach 2.2% and 4.1%, respectively (6.3% total). In parental JHU029 cells, early and late apoptosis were
7.7% and 15.4%, respectively (23.1% total apoptosis), robustly increasing in TSPAN1-depleted cells up
to 3.5% and 53.9% (57.4% total). Similarly, early and late apoptosis in resistant JHU029-R cells represent
7.1% and 27.9%, respectively (35% total), and apoptosis was markedly induced in TSPAN1-depleted
JHU029-R cells, reaching 7.4% and 42.2% (49.6% total). For parental HTB-43 cells, the early and late
apoptosis represent 2.4% and 1.9% respectively (4.3% total), respectively increasing to 3.3% and 4.2%
(7.5% total) by TSPAN1 depletion. For HTB-43-R cells, early and late apoptosis represent 4.0% and
6.1% respectively (10.1%) compared to 5.3% and 4.0% (9.3%) in TSPAN1-depleted cells (Figure 3B).
These results show that TSPAN1 depletion induces apoptosis in HNSCC cells.
3.4. TSPAN1 Depletion Downregulates Several Signaling Cascades with SRC Kinase Signaling as a
Central Node
Based on our previous report linking HNSCC chemoresistance and autophagy [20], the possible
relationship between TSPAN1 and autophagy was investigated. LC3 lipidated (LC3-II) (the most
universal marker of autophagy activation) and p62 proteins decreased at protein level in cells depleted
for TSPAN1 (ATG5 only decreased in parental CCL-138 cells) (Figure 4A and Figure S8). Autophagy
inhibition was confirmed by TEM (Figure 4B,C). Therefore, this inhibitory effect on autophagy might be
associated with the suppressive effect of TSPAN1 depletion on cell proliferation and apoptosis induction.
Given the fact that TSPAN1 inhibition sensitized both parental and the CDDP-resistant derivatives of
JHU029, HTB-43 and CCL-138 cells to dasatinib (Figure S3), we wonder whether phosphorylation of
SRC kinase (p-SRC or active SRC), a direct target of dasatinib, could be a mediator of TSPAN1 function
in our HNSCC models. In fact, p-SRC levels (an indicator of SRC activation) consistently decreased in
all six cell lines tested: JHU029, JHU029-R, HTB-43, HTB-43-R, CCL-138, CCL-138-R upon TSPAN1
depletion (Figure 4A). Notably, p-SRC levels correlate well with TSPAN1 expression and, although
expression is low in CSCs at G1, both proteins increase in CSCs at G3 (Figure S4A,B). Interestingly,
dasatinib robustly inhibited SRC activity and its major target p-SRC in our HNSCC models; however,
dasatinib did not alter the expression of various autophagy-related proteins or TSPAN1 (Figure S4B).
These findings indicate that TSPAN1 inhibition efficiently targets SRC-dependent and independent
signaling pathways, beyond merely mimicking the action of dasatinib as a SRC inhibitor.
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and PARP1 cleavage in parental nd CD P-resis S C cells upon TSPAN1 depletion. In the
CCL-138-R cell line, despite not observing TSP 1 inhibition at protein level (but it was inhibited at
the mRNA level), an induction of PARP1 was observed. Note: the lower band corresponds to cleaved
PARP1 (arrow). Vinculin was used for protein loading normalization. (B) Apoptosis analysis by FACS
using Annexin V expression kit. Representative scatter plots of propidium iodide (y-axis) vs. Annexin
V-APC (x-axis) to detect early (right bottom quadrant) and late (right upper quadrant) apoptosis in
parental and their respective CDDP-resistant cells (-R) JHU029, HTB-43 and CCL-138, comparing NC
vs. TSPAN1depleted cells.
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modulated by TSPAN1 depletion in HNSCC cells, including various key proteins related to autophagy and
SRC/AKT/ERK signaling pathways. (B) Representative electronic microscopy images in TSPAN1-depleted
cells vs. control cells (NC) in CCL-138 and CCL-138-R cells. TEM images revealed autophagosomes and
autophagolysosomes, characteristic features of autophagic cells. (C) Quantification of autophagic vesicles
from each experimental group. Note that auto hagy vesicles ecrease in CCL-138 c lls upon TSPAN1
depletion. Unpaired two-tailed Student’s t-test, *** (p < 0.001).
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It has also been recently described that TSPAN1 promotes epithelial-to-mesenchymal transition
(EMT) and metastasis in a cholangiocarcinoma cancer model [31]. This prompted us to study the link
between TSPAN1 and EMT in our HNSCC models. For this purpose, various EMT-related proteins
vimentin, E-cadherin and N-cadherin were analyzed by Western blot in TSPAN1-depleted cells vs. NC.
Only the expression of vimentin (a mesenchymal-related protein) decreased upon TSPAN1 inhibition in
JHU029 and JHU029-R cells, but no clear differences were observed in E-cadherin or N-cadherin, nor in
the other HNSCC cell lines [28]. Wang et al. [31] described that TSPAN1 promotes EMT acting through
ERK1/2 and AKT pathways. Western blot analysis of p-ERK1/2 and p-AKT was hence performed
to explore this possibility in our HNSCC models. p-AKT levels were found to decrease in CCL-138,
JHU029-R, HTB-43 and HTB-43-R cells upon TSPAN1 inhibition. p-ERK1/2 also decreased at varying
levelsin CCL-138, CCL-138-R, JHU029, JHU029-R, HTB-43 and HTB-43-R cells (Figure 4A). In JHU029-R,
CCL-138 and HTB-43 cells, dasatinib treatment decreased p-ERK1/2, but did not affect p-AKT levels
(Figure S4B).
3.5. TSPAN1 Depletion Decreases Tumor Formation and Metastatic Capacity in Mice
The role of TSPAN1 was investigated in HNSCC models in vivo, inducing mice tumors with
TSPAN1-depleted JHU029 and JHU029-R cells vs. control cells (NC). In such cells, TSPAN1 depletion
was confirmed (pre-injection) at protein level (Figure 5A and Figure S8). Tumors formed by JHU029 cells
phenotypically reproduced the characteristics observed in HNSCC patients (Figure S5A). Tumor sizes
were significantly lower in the tumors generated from TSPAN1-depleted cells compared to those formed
by control cells (Figure 5B,C and Figure S5B). Measurement of tumor size by IVIS bioluminescence
imaging further confirmed these results (Figure 5D,E). Notably, tumors formed by the resistant
JHU029-R cells, despite being smaller in size, showed EMT features, characteristic of fusocellular
morphology (Figure 5F, arrows). Moreover, the EMT phenotypes were reversed in tumors formed
by TSPAN1-depleted JHU029-R cells. At the endpoint of the experiment, we found that tumors from
the group JHU029-R siTSPAN1 generally showed lower TSPAN1 expression than the corresponding
control group (JHU029-R NC) (Figure S5C), beyond some variability in TSPAN1 levels among the
tumors from each experimental group. The pathological examination of the primary tumors generated
in mice showed no significant differences in Ki-67 staining regardless TSPAN1-depletion (Figure S5D).
The impact of TSPAN1 inhibition on metastasis formation was also evaluated ex vivo, thereby
monitoring the presence of luciferin-positive JHU029-R cells in various organs extracted from the
different mice using IVIS bioluminescence imaging system (Figure S6). A significant decrease in
bone and liver metastasis was measured in tumors originated from TSPAN1-depleted JHU029-R cells
compared to control cells, and a trend to significance in lung metastasis was also observed (Figure 5G).
Overall, TSPAN1 inhibition renders smaller tumors with reduced metastatic potential.
3.6. TSPAN1 Expression in Patient Samples. Correlations with Active SRC and EMT Features
The relevance of TSPAN1 expression was further investigated in patient biopsies. Firstly,
the expression of TSPAN1 was analyzed at mRNA level in 16 biopsies of tumor tissue and
patient-matched normal mucosa. In eight out of 16 patients, TSPAN1 mRNA was upregulated
(50% of cases) (Figure S7A,B). In silico analysis of TCGA database was performed to explore TSPAN1
mRNA expression more extensively in different cancer types [32]. It was revealed that TSPAN1 mRNA
was frequently and commonly upregulated in multiple cancers compared to the corresponding normal
counterparts, including HNSCC (Figure S7C).
Secondly, TSPAN1 protein levels were analyzed by Western blot in paired samples of laryngeal
and pharyngeal tumors (T) and patient-matched normal mucosa (N). TSPAN1 overexpression was
detected in eight out of 12 tumor samples compared to the normal counterparts (Figure 6A and
Figure S8). Of note, high TSPAN1 levels were also observed in some normal tissues comparable to
the matched tumor. To further and significantly extend these data, immunohistochemical analysis of
TSPAN1 were performed in a cohort of 106 laryngeal and pharyngeal cancer patients, and correlated
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with clinical data and disease outcome (Table S7). TSPAN1 protein expression in tumors exhibited
cytoplasmic and nuclear patterns that were separately scored, whereas TSPAN1 expression was
negligible in matched adjacent normal epithelia and stromal cells (Figure 6B). Although the cytoplasmic
expression of TSPAN1 has been reported, we have not found previous works describing nuclear
expression [26,31,33]. Forty-eight (45.2%) out of 106 patients showed cytoplasmic TSPAN1, and 34 of
them showed concomitant cytoplasmic and nuclear staining (32.1% of total) (Figure 6C). Based on our
data from HNSCC models, possible associations of TSPAN1 expression with p-SRC and E-cadherin
were assessed. Interestingly, cytoplasmic and nuclear TSPAN1 were both inversely and significantly
correlated with E-Cadherin expression (p = 0.001 and p = 0.04, respectively) (Figure 6D), confirming a
possible link between TSPAN1 and EMT in HNSCC. In agreement with our results in HNSCC cells,
TSPAN1 expression also correlated with active SRC (p = 0.035) (Figure 7A,B). In addition, we found
a borderline association of TSPAN1 expression with a poor degree of histological differentiation of
tumors (p = 0.055) (Figure 7C,D).Cancers 2020, 12, x FOR PEER REVIEW 13 of 21 
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siTSPAN1 and injected into immunosuppressed mice. TSPAN1 inhibition was monitored in cultured
cells at day 2 after transfection. (B) Graph representing the growth of mice tumors originated from
the indicated cell lines upon TSPAN1 inhibition vs. negative controls (NC). Data are expressed as
mean ± SD. Significant differences ere observe between JHU029 NC vs siTSPAN1 (days 10–28),
and JHU029-R NC vs siTSPAN1 (days 12–41). ir tudent’s t-test. (C) Pictures of the tumors
formed in the indicated group of mice. (D) Pictures of the mice tumors at the end point of the experiment.
Th lumin scent signal wa taken by the IVIS apparatus. (E) Quantification of the luminescent signals
of t ors were acquired by Living Image software, a d gr phed. Unpaire two-tailed Student’s t-test,
* (p < 0.05). (F) Representative images of H&E staining for the indicated mice tumors. Note th presence
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Figure 6. Protein expression study of TSPAN1 in human biopsies from HNSCC patients. (A) Western 
blot of TSPAN1 protein in laryngeal and pharyngeal cancer biopsies comparing tumor (T) vs. normal 
tissue (N). (B) Representative images of IHC staining for TSPAN1 and E-Cadherin proteins. The 
expression of TSPAN1 was only observed in the tumor tissue, showing either a cytoplasmic or a 
cytoplasmic and nuclear pattern. (C) Table summarizes the percentage of patients with positive 
expression for the indicated proteins in the studied cohort of 106 HNSCC patients. (D) Correlation 
between E-Cadherin and TSPAN1 expression. The plots show the expression of cytoplasmic TSPAN1 
(upper panel) and nuclear TSPAN1 (lower panel). χ² test and Fisher’s exact test. 
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(N). (B) Representative images of IHC staining for TSPAN1 and E-Cadherin proteins. The expression
of TSPAN1 was only observed in the tumor tissue, showing either a cytoplasmic or a cytoplasmic
and nuclear pattern. (C) Table summarizes the percentage of patients with positive expression for the
indicated proteins in the studied cohort of 106 HNSCC patients. (D) Correlation between E-Cadherin
and TSPAN1 expression. The plots show the expression of cytoplasmic TSPAN1 (upper panel) and
nuclear TSPAN1 (lower panel). χ2 test and Fisher’s exact test.
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Figure 7. Associations of TSPAN1 expression with active SRC and with the degree of tumor differentiation.
(A) Direct correlation of TSPAN1 expression with active SRC. χ2 test and Fisher’s exact test, * (p < 0.05).
(B) Representative IHC images for the different expression levels of active SRC (low, moderate and high).
(C) TSPAN1 expression tends to correlate with the degree of tumor differentiation, showing higher
TSPAN1 expression in patients with poorly differentiated tumors. (D) Representative IHC images to
illustrate TSPAN1 expression along different degrees of tumor differentiation (well, moderately and
poorly) as indicated.
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4. Discussion
Our results uncover TSPAN1 as a key protein in HNSCC pathogenesis, particularly in laryngeal
and pharyngeal cancer. In the present study, a proteomic screen revealed that TSPAN1 protein is
overexpressed in both CDDP-resistant cells and CSCs from CCL-138 cells. Regardless the endogenous
level of TSPAN1 expression in different HNSCC cell lines (CCL-138, JHU029 or HTB-43), its inhibition
by siRNAs, at RNA and protein level, consistently caused a decrease in proliferation and apoptosis
induction. Moreover, the induction of apoptosis provoked by TSPAN1 inhibition was concomitantly
accompanied by a decrease in autophagy. This result supports our previous findings indicating that
autophagy activation is a feature associated with resistant phenotypes in HNSCC cells and tumors [20].
Accordingly, TSPAN1 inhibition has been linked to decreased cell proliferation and apoptosis induction,
as previously reported in other cancer types. The upregulation of caspases 3 and 8, in conjunction with
the downregulation of Bcl-2, are linked to apoptosis activation in these studies [34–37].
Importantly, TSPAN1 depletion was found to sensitize resistant cells to the action of distinct
therapeutic drugs (i.e., CDDP and dasatinib), and this sensitization was more pronounced in
biopsy-derived primary cell lines from laryngeal and pharyngeal tumors in comparison to established
HNSCC cell lines. Although some reports have described several members of the tetraspanin family
(i.e., CD9, CD81, TSPAN8, CD51) associated with CSC properties and/or resistance to current therapies
in various cancer models [38–42]; as far as we know, this is the first time that TSPAN1 has been shown
to be involved in the cellular response to chemotherapy.
Upon TSPAN1 inhibition, a decrease in p-SRC activation occurs as a common feature in all
HNSCC cell lines tested, which was accompanied by a decrease in p-AKT and p-ERK1/2 levels.
Nevertheless, TSPAN1 depletion decreased p-ERK1/2 in both parental JHU029 and resistant JHU029-R
cells, while p-AKT levels only diminished in JHU029-R cells. Moreover, Vimentin was reduced in
both parental JHU029 and resistant JHU029-R cells upon TSPAN1 depletion, suggestive of a link
between TSPAN1 and the EMT process. However, vimentin reduction was not accompanied by an
induction of E-Cadherin or a decrease in N-Cadherin expression. Therefore, our results suggest that
SRC signaling is a major effector of TSPAN1 in these HNSCC models, with p-SRC emerging as a central
node. However, the effects of TSPAN1 depletion extend beyond solely regulating p-SRC activation
to also effectively target the levels of p-AKT, p-ERK1/2 and autophagy pathway. In marked contrast,
the action of a SRC inhibitor such as dasatinib in JHU029-R cells was restricted to decrease p-SRC and
p-ERK1/2 levels but did not affect p-AKT levels nor autophagy-related genes.
TSPAN1 has been described as a typical cell surface receptor that, like other tetraspanin family
members, could be involved in the activation of various signaling cascades through interactions with
other tetraspanins, integrins, receptors and/or cytoplasmic proteins (associations known as tetraspanin
web). Therefore, TSPAN1 could activate additional effectors, apart from p-SRC, to contribute to the
carcinogenesis process facilitating the acquisition of therapy resistance. In cholangiosarcoma and
HNSCC models, the interaction of TSPAN1 with integrins has been described [31,43]. It would be
worth to explore in the future if TSPAN1 activates p-SRC though the interaction with integrins or other
cell surface receptors -including its own putative dimerization [28] and also its translocation from
cytoplasmic to nuclear localization.
Interestingly, the biological effects of TSPAN1 depletion observed in vitro, were also corroborated
in vivo. In the xenografted mice, we found that tumors formed by resistant JHU029-R cells were smaller
in size but developed more metastasis than those formed by parental JHU029 cells [28]. Accordingly,
all resistant HNSCC cell lines showed reduced proliferate capacity in culture than the corresponding
parental cells. This can be due to the fact that resistant cells have a higher proportion of CSCs and
autophagy upregulation, as we previously reported [20]. This supports the notion that resistant tumors
(presumably enriched in number and features of CSCs and/or autophagy activation), are not necessarily
bigger in size or more proliferative. In fact, they are instead more aggressive, a characteristic frequently
observed in the clinic [44]. Specifically, CSC subpopulations are quite quiescent. Dynamic changes and
complex interactions in the tumor microenvironment play an integral part during tumor progression
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and metastasis, as an adaptive response to enhance CSC survival [45]. In this line of evidence, tumors
formed by slowly growing resistant cells JHU029-R showed a fusocellular pattern compared to parental
JHU029 cells. Such pattern is associated with EMT features, which are typically prominent in aggressive
and resistant tumor phenotypes [46]. Moreover, in tumors formed by resistant JHU029-R cells, TSPAN1
inhibition was able to revert the fusocellular pattern to an epithelial morphology and reduce metastasis
capacity of these resistant HNSCC cells. These results confirm the oncogenic role of TSPAN1 in vivo in
our laryngeal cancer model and suggest a putative role of TSPAN1 in EMT, supporting the observations
described by Wang et al. in a cholangiocarcinoma model [31].
Importantly, the IHC and Western blot analysis of TSPAN1 in HNSCC patient biopsies, further
confirm the potential oncogenic role of TSPAN1 in HNSCC pathogenesis. Thus, TSPAN1 expression was
detected in ~45% (IHC) of laryngeal and pharyngeal tumors, a similar percentage to the upregulation of
TSPAN1 detected at mRNA level (8 out of 16 patients) and also by Western blot (eight out of 12 patients).
In good agreement, the overexpression of TSPAN1 in human cancer vs. adjacent non-cancerous tissue
has been widely documented in cholangiocarcinoma [31,47,48], skin squamous cell carcinoma [36,49],
esophageal carcinoma [34], ovarian carcinomas [50], prostate cancer [26], pancreatic cancer [35,37] and
gastric carcinoma [51,52]. Moreover, TSPAN1 expression has been associated with HPV infection in
cervical carcinomas, and considered an important diagnostic and prognostic marker, as strong TSPAN1
expression was found in a subset of high-grade cervical cancers and in most of the undifferentiated
squamous cell carcinomas [53–55].
TSPAN1 protein showed predominantly a cytoplasmic and nuclear pattern inHNSCC specimens,
whereas TSPAN1 expression was negligible in stromal cells and adjacent normal epithelia. Moreover,
the IHC analysis on patient samples also corroborates the strong correlation between TSPAN1 and SRC
activation previously observed in our HNSCC models. Similarly, IHC data also demonstrated an inverse
correlation between cytoplasmic and nuclear TSPAN1 and E-Cadherin expression, thus reinforcing our
in vitro findings suggesting a possible link between TSPAN1 and EMT. In addition, TSPAN1 expression
was more frequently detected in poorly differentiated tumors (with higher EMT features) than in well
differentiated (57% vs. 31%) (Figure 7). Together these results strongly support the involvement of
TSPAN1 in EMT promotion in HNSCC.
Hence, all these observations lead us to propose for the first time TSPAN1 as an oncogenic protein
involved in HNSCC chemoresistance, as well as in HNSCC development and progression, with p-SRC
emerging as a predominant downstream effector. Moreover, TSPAN1 overexpression is associated to the
development of an EMT program as consistently observed in mice tumors and HNSCC patient biopsies.
Our findings support the notion that SRC activation may contribute to metastatic dissemination in
HNSCC [25] and provide additional evidence extending the association of SRC activation with EMT to
other HNSCC subtypes (i.e., laryngeal and pharyngeal carcinoma) beyond previous observations in
nasopharyngeal carcinoma [56].
According to the herein presented data, we anticipate that TSPAN1 inhibition could represent
a promising candidate for targeted therapy against laryngeal and pharyngeal cancers and possibly
other HNSCC subsites. The fact that inhibition of TSPAN1 is able to sensitize resistant cells to different
chemotherapeutic agents, has an important added value to be considered a potential novel target for
cancer therapy.
5. Conclusions
Here, we described that TSPAN1 is a novel oncogenic protein associated with HNSCC
chemoresistance, with SRC kinase signaling emerging as a central node. Mice tumors formed by
cisplatin-resistant HNSCC cells showed a fusocellular pattern compared to parental cells. Importantly,
TSPAN1 inhibition was able to revert this fusocellular pattern to an epithelial morphology, and also
to reduce metastatic spreading. Consistent with these data, TSPAN1 expression in HNSCC patient
biopsies was also correlated with EMT features and SRC activation.
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